Physician profile
Jeffrey E Jarrett
NPI 1023026663
$4,600.83
in general payments reported to CMS, 2019-2025
34 companies · $3,257 in 2025
The $3,257 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $86.93 · 2021: $13.01 · 2022: $221 · 2023: $177 · 2024: $351 · 2025: $3,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,108 · Food and Beverage: $1,487 · Education: $117 · Travel and Lodging: $72.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,108.00 |
| Food and Beverage | $1,487.49 |
| Education | $117.37 |
| Travel and Lodging | $72.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,631.87 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $244.87 | 2019 | |
| Grifols USA, LLC | $203.49 | 2019-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $149.16 | 2019-2025 | |
| Philips North America LLC | $139.43 | 2022-2025 | Vest Therapy Und |
| Amgen INC. | $136.49 | 2023-2025 | Tezspire |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Resmed Corp | $96.31 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.20 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $67.70 | 2024-2025 | Glassia |
| Harmony Biosciences LLC | $59.17 | 2022-2024 | Wakix |
| Glaxosmithkline, LLC. | $59.16 | 2019-2025 | Nucala |
| Merck Sharp & Dohme LLC | $55.73 | 2023-2024 | Keytruda |
| Verona Pharma, INC. | $54.31 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $43.42 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $43.25 | 2019-2023 | Dupixent |
| Mylan Specialty L.P. | $42.86 | 2019 | |
| Abiomed | $38.29 | 2025 | |
| Tactile Systems Technology INC | $35.07 | 2025 | Flexitouch Plus, Nimbl |
| Insmed, INC. | $34.26 | 2025 | Arikayce |
| Baxter Healthcare | $34.20 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Bayer Healthcare Pharmaceuticals INC. | $31.37 | 2024-2025 | |
| 3b Medical, INC. | $30.03 | 2025 | Luna |
| Genentech USA, INC. | $25.57 | 2019 | |
| United Therapeutics Corporation | $19.66 | 2025 | Orenitram, Remodulin |
| Csl Behring | $17.90 | 2019 | |
| Allergan, INC. | $17.59 | 2020 | |
| Inspire Medical Systems, INC. | $16.14 | 2023 | Inspire |
| Axsome Therapeutics, INC. | $14.30 | 2023 | Sunosi |
| Pfizer INC. | $13.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.94 | 2024 | Fasenra |
| Avadel Cns Pharmaceuticals, LLC | $13.15 | 2024 | Lumryz |
| Novartis Pharmaceuticals Corporation | $12.21 | 2019 | |
| Veran Medical Technologies, INC. | $9.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Jarrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.